Management of Valvular Heart Disease

Assessment and Monitoring

The European Society of Cardiology recommends regular echocardiographic monitoring every 1-2 years for patients with moderate aortic regurgitation (AR) 1, 2
The American College of Cardiology suggests monitoring for development of symptoms, decrease in left ventricular ejection fraction (LVEF) below 55%, increase in left ventricular end-systolic dimension (LVESD) >50mm or indexed LVESD >25mm/m², and progression of aortic root dilatation 2, 3
A dilated ascending aorta (44mm) requires monitoring but does not yet meet criteria for surgical intervention, according to the European Heart Journal and Circulation 4, 5

The American Heart Association recommends avoiding beta-blockers in patients with bradycardia and AR, as they can worsen regurgitation by prolonging diastolic filling time 6
The European Society of Cardiology suggests treatment with vasodilators that do not slow heart rate is reasonable (Class IIa, Level C-LD) for patients with chronic AR 6
Consider ACE inhibitors or dihydropyridine calcium channel blockers for symptomatic improvement in AR, as recommended by the European Heart Journal 1, 7

The American College of Cardiology indicates surgery would be necessary if the patient develops symptoms attributable to valvular disease, LVEF <55%, LVESD >50mm or indexed LVESD >25mm/m², or aortic root dilatation ≥50mm (especially with bicuspid valve) or ≥55mm 2, 3
The European Heart Journal and Circulation suggest surgical intervention is necessary for aortic root dilatation ≥50mm or ≥55mm 4, 5

The combination of AR and AS creates increased afterload due to both regurgitant volume and relatively small aortic valve area, according to the Journal of the American College of Cardiology 8, 9
Patients with mixed valve disease may develop symptoms at earlier intervals than those with isolated valve lesions, as suggested by the Journal of the American College of Cardiology 8, 9

The American Heart Association recommends careful attention to volume status and avoidance of bradycardia in perioperative management for patients with AR undergoing non-cardiac surgery 10
Intensive monitoring is appropriate in the immediate postoperative period for any surgery, according to Circulation 10

Elevated systemic blood pressure caused by Adderall increases left‑ventricular afterload, which can theoretically enlarge regurgitant volume in patients with aortic or mitral regurgitation. 11
In individuals with moderate‑to‑severe valvular regurgitation, any stimulant‑induced rise in afterload may accelerate progression to symptoms or left‑ventricular dysfunction, warranting closer cardiovascular monitoring. 11

Epidemiologic data show that amphetamine‑based stimulants (including mixed amphetamine salts) and methylphenidate are not associated with the development of structural valvular heart disease, in contrast to fenfluramine‑type agents that act on 5‑HT₂B receptors. [12][13]
Phentermine used as monotherapy (i.e., without fenfluramine) has not demonstrated an excess prevalence of valvular heart disease in population studies. [12][13]

Contraindication: Adderall should be avoided in patients with severe, symptomatic aortic or mitral regurgitation who are awaiting surgical intervention, because even modest blood‑pressure elevations could worsen the lesion. 11
Monitoring guidance: For patients with mild regurgitation, routine blood‑pressure and heart‑rate checks are sufficient; for moderate‑to‑severe disease, serial echocardiography and tighter hemodynamic surveillance are advised. (Derived from the same hemodynamic risk evidence.) 11